Galectin Therapeutics announces new CEO

|About: Galectin Therapeutics, Inc. (GALT)|By:, SA News Editor

Galectin Therapeutics (NASDAQ:GALT) announces that Harold H. Shlevin, Ph.D., currently the Company’s COO, has been appointed CEO and President to succeed Peter G. Traber, M.D., who resigns as President, CEO and Chief Medical Officer. The transition will be effective July 6.

Prior to his work at Galectin, Dr. Shlevin served Georgia Institute of Technology’s Advanced Technology Development Center as manager of bioscience partnering and commercialization efforts.